「pma」の検索結果

Agent fallback for CDedicatedServerWorkshopManager_SwitchToWorkshopMapGroup (auto-generated, category: func). Locate CDedicatedServerWorkshopManager::SwitchToWorkshopMapGroup in the CS2 server module via IDA Pro MCP and emit a fresh, minimal-unique artifact. The deterministic preprocessor could not resolve this symbol on the current gamever - your job is the re-sign. Trigger: CDedicatedServerWorkshopManager_SwitchToWorkshopMapGroup, CDedicatedServerWorkshopManager::SwitchToWorkshopMapGroup

日本語の概要は準備中です。原文の説明を表示しています。

Agent fallback for CDedicatedServerWorkshopManager_SwitchToWorkshopMapGroup-decompiles (auto-generated, category: func). Locate CDedicatedServerWorkshopManager::SwitchToWorkshopMapGroup in the CS2 server module via IDA Pro MCP and emit a fresh, minimal-unique artifact. The deterministic preprocessor could not resolve this symbol on the current gamever - your job is the re-sign. Trigger: CDedicatedServerWorkshopManager_SwitchToWorkshopMapGroup-decompiles, CDedicatedServerWorkshopManager::SwitchToWorkshopMapGroup

日本語の概要は準備中です。原文の説明を表示しています。

Appmachine integration. Manage data, records, and automate workflows. Use when the user wants to interact with Appmachine data.

日本語の概要は準備中です。原文の説明を表示しています。

Query the Cancer Dependency Map (DepMap) for cancer cell line gene dependency scores (CRISPR Chronos), RNAi DEMETER2 scores, PRISM compound sensitivity, and gene effect profiles across the cell-line panel. Use for identifying cancer-selective vulnerabilities, separating pan-essential genes from selective ones, finding synthetic lethal interactions, correlating dependency with mutation, expression and copy number, and validating oncology drug targets. Also trigger on DepMap, Chronos gene effect, CRISPRGeneEffect.csv, DEMETER2, PRISM repurposing, co-essentiality, pan-essential, or ACH- cell line identifiers.

日本語の概要は準備中です。原文の説明を表示しています。

Product marketing and go-to-market strategy for B2B SaaS launches and positioning. Use this skill when planning a product launch, developing positioning and messaging, analyzing competitive landscape, building customer advocacy programs, designing a customer referral program (who may accept the reward, how the introduction is made), designing a win/loss interview program, working out why we lose deals, designing GTM strategy, creating category positioning, planning analyst briefings, or deciding which country to expand into and how far to localize. Also use it for an early-stage startup where the founder is still doing the selling — running founder-led sales, setting up a design-partner program, judging whether you have product-market fit, deciding what not to do yet, deciding when to hire the first AE or first marketer, and moving upmarket to larger buyers. Also use it when your company has just acquired another (or is about to), to plan the marketing integration: what you may and may not do between signing and close, the first letter to the acquired customers, whether to keep, endorse, fold in or retire the acquired brand, merging the two marketing databases without mailing people who opted out, when to start cross-selling, and announcing a product sunset. Also use it to design a demand-generation campaign and the channel plan it runs on: one campaign with one job, the offer for buyers who are and are not in market, what each channel is for, the kill and scale rules set before launch, the follow-up sales agrees to, the yearly calendar of always-on programs and tentpole campaigns, and which channels to keep, test or stop. Also use it for brand marketing and demand creation — how much to spend on brand versus performance, what to measure when a brand campaign produces no conversion event, and how to answer "we cannot attribute it". Also triggers on: founder-led sales, founder-led GTM, design partners, design partner agreement, first customers, first 10 customers, do we have product-market fit, PMF, Sean Ellis test, very disappointed survey, pre-seed, seed stage, when to hire our first AE, first sales hire, first marketing hire, moving upmarket, going upmarket, enterprise readiness, first enterprise deal, what do enterprise buyers need before they sign, positioning, product launch, beta program, early access program, design partners, private preview, public preview, general availability, GA launch, when can we call it GA, can sales sell a beta feature, selling the roadmap, launch tier, competitive intelligence, messaging, customer advocacy, win/loss analysis, win/loss interviews, why we lose deals, closed-lost analysis, loss reason, close-reason field, competitive displacement, displace an incumbent, rip and replace, competitive takeout, switch from a competitor, win deals from a competitor, incumbent contract, renewal window, auto-renewal notice period, switching costs, EU Data Act, cloud switching rights, why do we lose to no decision, GTM, category design, ideal customer profile, ICP, what is our real ICP, who actually buys from us, refresh our ICP from closed-won deals, ICP refresh before planning, analyst briefing, G2 review, international expansion, market entry, expand into Europe, which country should we launch in next, localization, translate our site, in-country go-to-market, regional GTM, is cold email legal in Germany, brand marketing, brand awareness, brand vs performance, brand versus demand gen, demand creation, demand capture, 95-5 rule, out of market buyers, category entry points, distinctive brand assets, mental availability, brand tracking, brand health, brand lift, share of search, how do we measure brand, justify brand spend, brand budget. Also triggers on public-sector marketing: sell to government, government marketing, public sector go-to-market, federal marketing, state and local government, SLED, FedRAMP, FedRAMP marketing claims, can we say FedRAMP ready, GovRAMP, StateRAMP, VPAT, accessibility confor

日本語の概要は準備中です。原文の説明を表示しています。

Retrieves and analyzes Cancer Dependency Map (DepMap) release data, including CRISPR Chronos gene effects, cancer model annotations, omics biomarkers, and PRISM drug sensitivity. Supports cancer-selective dependency, co-essentiality, and candidate synthetic-lethality analyses with release-aware identifiers and statistical checks.

日本語の概要は準備中です。原文の説明を表示しています。

FDA regulatory consultant for medical device companies. Provides 510(k)/PMA/De Novo pathway guidance, QMSR (21 CFR 820, which incorporates ISO 13485:2016 by reference since 2026-02-02; formerly QSR) compliance, HIPAA assessments, and device cybersecurity. Use when user mentions FDA submission, 510(k), PMA, De Novo, QMSR, QSR, ISO 13485 for FDA, premarket, predicate device, substantial equivalence, HIPAA medical device, or FDA cybersecurity.

日本語の概要は準備中です。原文の説明を表示しています。

Senior Regulatory Affairs Manager for HealthTech and MedTech companies. Prepares FDA 510(k), De Novo, and PMA submission packages; analyzes regulatory pathways for new medical devices; drafts responses to FDA deficiency letters and Notified Body queries; develops CE marking technical documentation under EU MDR 2017/745; coordinates multi-market approval strategies across FDA, EU, Health Canada, PMDA, and NMPA; and maintains regulatory intelligence on evolving standards. Use when users need to plan or execute FDA submissions, navigate 510(k) or PMA approval processes, achieve CE marking, prepare pre-submission meeting materials, write regulatory strategy documents, respond to agency queries, or manage compliance documentation for medical device market access.

日本語の概要は準備中です。原文の説明を表示しています。

FDA regulatory consultant for medical device companies, covering 510(k)/PMA/De Novo pathways, QSR (21 CFR 820), HIPAA, and device cybersecurity. Use for FDA submissions, predicate and substantial-equivalence analysis, and premarket strategy.

日本語の概要は準備中です。原文の説明を表示しています。

DepMap CRISPR gene effect (Chronos) analysis: sign convention for essentiality, per-gene NaN-safe Spearman correlation, data loading/alignment. For general NaN-safe correlation see nan-safe-correlation; for quality filtering see degenerate-input-filtering.

日本語の概要は準備中です。原文の説明を表示しています。

Systematic application of the eight privacy design patterns per Hoepman: minimize, hide, separate, abstract, inform, control, enforce, and demonstrate. Covers pattern selection methodology per processing activity, mapping to GDPR principles, and practical implementation guidance for privacy-by-design system architecture.

日本語の概要は準備中です。原文の説明を表示しています。

Bu template'i klonladiktan sonraki tum kurulumu yurutur — bagimliliklar ve codegen, projeyi kendine uyarlama, Firebase, giris yontemleri (Google/Apple/e-posta dogrulama/misafir gezinme), zorunlu guncelleme (Remote Config), odeme ve abonelik (RevenueCat), Android release imzalama (keystore), native splash ve store URL'leri. Kullaniciya ne istedigini sorar, AppConfig bayraklarini cevirir ve Firebase Console / Apple Developer / Play Console / RevenueCat tarafinda yapmasi gerekenleri sirayla listeler. Kullanici "kurulumu yap", "kurulumu baslat", "klonladim ne yapmaliyim", "Firebase'i bagla", "odeme ekle", "keystore olustur", "release imzasi kur", "set up the project" dediginde kullan. Repoyu ilk kez calistiran icin GIRIS NOKTASIDIR.

日本語の概要は準備中です。原文の説明を表示しています。

AMD ROCm / HIP GPU コンピューティングリファレンス。 hipMalloc, hipLaunchKernelGGL, HIP Graph, HIPRTC, hipify, rocBLAS, MIOpen, RCCL, rocprofv3, amd-smi, rocminfo, CDNA1-4 / RDNA1-4, MI300 / MI350, gfx942, Matrix Core, wave32/64。

Analyzes pooled CRISPR screen FASTQ reads and guide-count matrices with MAGeCK, validates guide libraries and contrasts, measures replicate and library QC, and produces gene hit rankings with effect sizes and FDR. Use for new knockout, CRISPRi, or CRISPRa screen analysis, enrichment or depletion contrasts, and MAGeCK count/test workflows; existing public dependency-score lookup belongs to DepMap.

日本語の概要は準備中です。原文の説明を表示しています。

Use when designing a prospective clinical study before submission — selecting and classifying endpoints (primary / key-secondary / exploratory, with surrogate-endpoint flagging), estimating sample size and power for two-arm designs (means / proportions / survival), or scoring a study plan for feasibility and a GO / GO-WITH-CONDITIONS / REDESIGN / NO-GO phase-gate decision. Every output is an ESTIMATE plus a named human owner (clinician / biostatistician / regulatory owner) — never clinical fact, never a finished protocol. Distinct from ra-qm-team, which handles the regulatory/QM submission (ISO 13485, EU MDR, FDA 510(k)/PMA/QSR), not the study design.

日本語の概要は準備中です。原文の説明を表示しています。

可重跑的数学计算与反例实验。用于 SymPy 精确代数/微积分/方程/矩阵、NumPy/SciPy 数值方法、mpmath 高精度交叉检查、OEIS 序列识别、有限范围反例搜索和计算证据记录。

日本語の概要は準備中です。原文の説明を表示しています。

MNN Vulkan 后端 kernel/算子性能优化与新特性集成。覆盖 benchmark 基线、kernel 优化迭代、集成验证全流程，以及 GLSL .comp + makeshader 双轨、conv1x1/attention dispatcher 多路径（coopMat/subgroup/nosubgroup）、cooperative matrix、packed weight 设计、pipeline cache、CPU 侧调度瓶颈、Adreno/Mali/Apple 多 vendor 真机验证等参考知识。

日本語の概要は準備中です。原文の説明を表示しています。

Audit Google Ads measurement, Search, Shopping, Performance Max, Demand Gen, YouTube-linked inventory, keywords and search terms, negative-keyword generation or review, creative assets, bidding, budgets, settings, and policy. Use for Google Ads, AdWords, Search campaigns, search terms reports, broad negatives, Shopping, Performance Max, PMax, Demand Gen, GAQL, Google conversion tracking, or Google campaign optimization.

日本語の概要は準備中です。原文の説明を表示しています。

Build sharp, physically coherent high-resolution materials for 3D rendering with appropriate PBR maps, texel density, UV direction, mipmaps, anisotropic filtering, and progressive asset delivery. Use for detailed wood, stone, fabric, foliage, and architectural close-ups without excessive download or GPU memory costs.

日本語の概要は準備中です。原文の説明を表示しています。

Given your total budget, recommends the optimal split across Google Search, PMax, Meta prospecting, Meta retargeting, and any other active channels based on your last 60-90 days of marginal ROAS and CPA by channel. Tells you where each additional dollar produces the best return. Platform: Google and Meta.

日本語の概要は準備中です。原文の説明を表示しています。

Plan, validate, and safely publish Google Ads assets, including sitelinks, callouts, structured snippets, image assets, and Performance Max asset briefs. Use when asked for Google Ads assets, ad extensions, sitelinks, callouts, snippets, image assets, Performance Max assets, PMax creative, or an asset audit.

日本語の概要は準備中です。原文の説明を表示しています。

Query openFDA API for drugs, devices, adverse events, recalls, regulatory submissions (510k, PMA), substance identification (UNII), for FDA regulatory data analysis and safety research.

日本語の概要は準備中です。原文の説明を表示しています。

[omh] Agent control of a robot, 3D printer, or IoT relay: gate robots, 3D printers, IoT relays, sensors, and lab hardware before trials; use external-connector-readiness for provider or connector adoption and toolbelt-readiness for missing control tools. Use when the user says: physical-device-readiness, physical device readiness, device safety readiness, physical device safety, hardware safety gate, 3d printer readiness, 3D printer safety, snapmaker printer safety.

日本語の概要は準備中です。原文の説明を表示しています。

Apply Martin Kleppmann-inspired data-system rules when designing reliability, scalability, consistency, replication, transactions, streams, or schema evolution.

日本語の概要は準備中です。原文の説明を表示しています。